Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong

You may also be interested in...



Pfizer R&D In China: Building A Virtual R&D Network

While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual research network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part one of the interview; part two will appear in an upcoming issue of PharmAsia News.

Pfizer R&D In China: Building A Virtual R&D Network

While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual research network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part one of the interview; part two will appear in an upcoming issue of PharmAsia News.

AstraZeneca Outsources Drug Discovery Research To BioDuro For Respiratory And Inflammation Indications

SHANGHAI - AstraZeneca is expanding its research collaboration with contract research organization BioDuro to cooperate on drug discovery research in respiratory and inflammation diseases in China, the two companies announced March 23

Related Content

UsernamePublicRestriction

Register

SC067215

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel